Skip to main content
. 2019 Sep 26;33(11):12915–12928. doi: 10.1096/fj.201900803R

Figure 4.

Figure 4

miR-106a-5p inhibits EMT in NPC by suppressing SMAD5 expression. The cells used for following assays were treated with empty vector, miR-106a-5p inhibitor, miR-106a-5p mimic, and siRNA-SMAD5 alone or in combination. A) Cell line that presented the lowest miR-106a-5p was screened. #P < 0.05 vs. normal cell line NP69; &P < 0.05 vs. NPC cell line CNE2. B) MiR-106a-5p expression and mRNA expression of SMAD5, E-cadherin, N-cadherin, MMP-9, Snail, and Vimentin determined by qRT-PCR. C) Gray value analysis of SMAD5, E-cadherin, N-cadherin, MMP-9, Snail, and Vimentin. D) Protein expression of SMAD5, E-cadherin, N-cadherin, MMP-9, Snail, and Vimentin detected by Western blot analysis. E, F) Cell proliferation detected by the EdU assay. G, H) Cell migration determined by the Transwell assay. I, J) The effect of miR-106a-5p on CNE2 cell migration detected by the scratch test. Measurement data were expressed as means ± sd. Comparisons among multiple groups were analyzed by 1-way ANOVA, followed by Tukey’s post hoc test. The experiment was repeated 3 times. *P < 0.05 vs. the NC group; #P < 0.05 vs. the miR-106a-5p inhibitor group.